Related Experiment Video
Updated: Oct 14, 2025

High-Throughput Transcriptome Analysis for Investigating Host-Pathogen Interactions
Published on: March 5, 2022
Identification of hub genes and molecular subtypes in COVID-19 based on WGCNA
1Department of Gastrointestinal Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan, China. sry_lidan@sina.com.
Insights
Researchers identified three molecular subtypes of Coronavirus disease 2019 (COVID-19) with distinct gene activation patterns. These subtypes may explain the varied clinical presentations and outcomes observed in COVID-19 patients.
Area of Science:
- Genomics
- Molecular Biology
- Infectious Diseases
Background:
- Coronavirus disease 2019 (COVID-19) exhibits significant heterogeneity in clinical manifestations and mortality.
- This variability may stem from underlying molecular differences within the patient population.
- Identifying these molecular subtypes is crucial for improving disease management and patient outcomes.
Purpose of the Study:
- To classify Coronavirus disease 2019 (COVID-19) patients into distinct molecular subtypes.
- To identify key genes and biological pathways associated with each identified subtype.
- To understand the molecular basis of clinical heterogeneity in COVID-19.
Main Methods:
- Whole-genome sequencing data from COVID-19 patients and healthy controls were analyzed.
- Consistent clustering was employed to classify patients into molecular subtypes.
- Weighted gene co-expression network analysis (WGCNA) and differential gene expression analysis were performed.
- Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted.
Main Results:
- Three distinct molecular subtypes of COVID-19 were identified.
- Significant differences in gene activation and pathway enrichment were observed between subtypes.
- Eleven hub genes, including RSAD2, IFIT1, and MX1, were identified as critical for differentiating subtypes.
Conclusions:
- Distinct molecular subtypes of COVID-19 exist, characterized by unique gene activation profiles.
- These molecular differences likely contribute to the observed heterogeneity in clinical symptoms and prognosis.
- Understanding these subtypes offers potential for more targeted therapeutic strategies.
Objective:
The heterogeneity of clinical manifestations and mortality rates in Coronavirus disease 2019 (COVID-19) patients may be related to the existence of molecular subtypes in COVID-19. To improve current management, it is essential to find the hub genes and pathways associated with different COVID-19 subtypes.
Materials And Methods:
The whole-genome sequencing information (GSE156063, GSE163151) of nasopharyngeal swabs from normal subjects and COVID-19 patients were downloaded from the Gene Expression Omnibus (GEO) database. The molecular subtypes of patients with COVID-19 were classified using the "consistent clustering" method, and the specific genes associated with each subtype were found. Differentially expressed genes (DEGs) were screened between normal subjects and COVID-19 patients; the Weighted gene co-expression network analysis (WGCNA) method was used to find the key module genes of COVID-19 patients. Subtype-specific, differentially expressed and module-related genes were collected and intersected. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were carried out and protein-protein interaction (PPI) networks were generated. The pathways enriched in COVID-19 subtypes were analyzed by gene set variation analysis (GSVA).
Results:
Patients with COVID-19 were divided into three subtypes, and there was no significant difference in gender and age distribution between subtypes. 82 differential gene pathways were screened between Subtypes I and II, 131 differential gene pathways were screened between Subtypes I and III, and 107 differential gene pathways were screened between Subtypes II and III. Finally, 44 differentially expressed key genes were screened, including 11 hub genes (RSAD2, IFIT1, MX1, OAS1, OAS2, BST2, IFI27, IFI35, IFI6, IFITM3, STAT2).
Conclusions:
There are significant differences in gene activation and pathway enrichment among different molecular subtypes of COVID-19, which may account for the heterogeneity in clinical presentation and the prognosis of patients.
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Canonical Wnt Signaling Pathway

